AstraZeneca's COVID-19 vaccine trial to resume in U.S.


WASHINGTON, Oct. 23 (Xinhua) -- Multinational pharmaceutical company AstraZeneca said on Friday it will resume the trial of its experimental COVID-19 vaccine in the United States, which has been paused since September.

The company said the U.S. Food and Drug Administration (FDA) authorized the restart of the trial in the United States on Friday, following the resumption of trials in other countries in recent weeks.

The FDA reviewed all safety data from trials globally and concluded it was safe to resume the trial, said the company in a statement.

As part of the standard review process for trial safety events, a voluntary pause to vaccination across all global trials was triggered on Sept. 6 to allow the examination of safety data by independent monitoring committees, according to the company.

The recommendations from these reviews have been supported by international regulators, who also confirmed that the trials were safe to resume, said the statement.

AstraZeneca said results from the late-stage trials are expected later this year.

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 18
Cxense type: free
User access status: 3
   

Did you find this article insightful?

Yes
No

Next In World

Australia cancels citizenship of Muslim cleric in local first
EU says Ethiopia fighting destabilising region, urges ceasefire
YouTube bans One America News Network from posting new videos for a week
Nearly 100 whales die after mass stranding in New Zealand
Ethiopia sent home soldiers of Tigrayan ethnicity from U.N. force in South Sudan - sources
‘Big Brother’ Amazon targeted in fight with Ambani over retailer
Japan fights coronavirus in luxurious style with million-yen masks
South Korean protests fan COVID-19 fears
Thailand criticised over royal insult charges as more summoned
Google must disclose emails in Russian oligarch’s divorce

Stories You'll Enjoy